Company Profile

Fermalogic Inc (AKA:Ferma Logic Inc.)
Profile last edited on: 5/28/21      CAGE: 45RU4      UEI:

Business Identifier: Erythromycin biosynthesis and actinomycete metabolism research.
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

920 North Franklin Street Suite 202
Chicago, IL 60610
   (312) 255-1090
Location: Single
Congr. District: 07
County: Cook

Public Profile

Fermalogic is a basic research company that explores metabolism using actinomycetes as our model living system. Applications for our research have been developed for pharmaceutical manufacturing as well as new therapeutics and nutraceutical development. Fermalogic’s core expertise is in the handling and manipulation of actinomycetes, which are used in industrial fermentations for the biosynthetic production of antibiotics, anticancer agents, immunosuppressants, and other natural products. Fermalogic also has pioneered the area of co-product recovery from industrial fermentations. Fermalogic’s first technology in co-product development applies to the recovery of isoflavones (genistein and daidzein), from soy-bean based fermentations particularly the erythromycin fermentation Fermalogic is independently owned and operated. Our offices were recently moved into new space that combines offices with a micro/molecular biology lab, still within the Franklin Square complex in Chicago’s River North area, after having moved out of the Chicago Technology Park in May of 2011. In addition Fermalogic has provided consulting and contract research to the pharmaceutical and agricultural industries including Novartis (Sandoz), Dow Agrosciences, Roussel-Uclaf, and Polfa Tarch

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2009 1 NIH $237,825
Project Title: Engineering Industrial Fermentations For Renewable Amino Acid Coproducts
2008 2 NIH $702,109
Project Title: Industrial Metabolic Engineering
2007 1 NIH $380,417
Project Title: Metabolic engineering of the methylmalonyl-CoA node in S. erythrea
2005 2 NIH $1,065,551
Project Title: Antibiotic Gene Clusters
2005 1 NIH $404,334
Project Title: Engineering metabolic flow for rapamycin production

Key People / Management

  J Mark Weber -- President & Senior Investigator

  Igor I Brikin -- Senior Investigator

  William H Cernota -- Research Scientist

  Andrew R Reeves

  Roy K Wesley -- Chief Financial Officer